# KEYNOTE-991 (NCT04191096)

> Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab plus enzalutamide
- Indication: metastatic hormone-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04191096
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Metastatic Hormone-Sensitive Prostate Cancer
- Interventions: Pembrolizumab; Enzalutamide; Androgen Deprivation Therapy (ADT); Placebo
- Enrollment: 1251
- Primary outcome: Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on KEYNOTE-991 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- Podcasts: 4
- YouTube: 2

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keynote-991-nct04191096

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04191096", "email": "<work email>"}; the inbox owner confirms by the emailed link.